New one-year results from 413 patients in the global EXPAND study of Abbott’s next-generation MitraClip mitral valve repair system demonstrate the benefits of MitraClip in a broad population of patients with functional (secondary) mitral regurgitation (MR).
The study, which is the largest contemporary real-world study of the MitraClip NTR/XTR system, showed that mitral valve repair with the system led to significant reductions in MR and improvements in heart failure symptoms with hospitalization and mortality rates comparable to the rates seen in the pivotal COAPT trial of MitraClip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?